U.S. Markets closed
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow 30

    31,097.26
    +321.83 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.11 (+0.90%)
     
  • Russell 2000

    1,727.76
    +19.77 (+1.16%)
     
  • Crude Oil

    108.46
    +2.70 (+2.55%)
     
  • Gold

    1,812.90
    +5.60 (+0.31%)
     
  • Silver

    19.85
    -0.50 (-2.44%)
     
  • EUR/USD

    1.0426
    -0.0057 (-0.5422%)
     
  • 10-Yr Bond

    2.8890
    -0.0830 (-2.79%)
     
  • Vix

    26.70
    -2.01 (-7.00%)
     
  • GBP/USD

    1.2103
    -0.0072 (-0.5930%)
     
  • USD/JPY

    135.1750
    -0.5530 (-0.4074%)
     
  • BTC-USD

    19,305.98
    +31.82 (+0.17%)
     
  • CMC Crypto 200

    420.84
    +0.70 (+0.17%)
     
  • FTSE 100

    7,168.65
    -0.63 (-0.01%)
     
  • Nikkei 225

    25,935.62
    -457.42 (-1.73%)
     

Quidel Rallies On Earnings Beat Despite Sales Decline

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

By Sam Boughedda

Investing.com -- Quidel Corporation (NASDAQ:QDEL), the diagnostic healthcare products manufacturer, reported its fourth quarter numbers after the bell Thursday, beating analyst expectations on revenue and earnings.

The company's shares have rallied over 15% as a result.

Quidel posted earnings per share of $7.29 on revenue of $636.9 million. Analysts polled by Investing.com anticipated EPS of $5.61 on revenue of $540.9 million.

However, revenue fell from the $809.2 million reported in the fourth quarter of 2020.

Quidel said the decline was caused mainly by a $249 million revenue decline of the Sofia 2 Flu + SARS antigen FIA. In addition, there was a shift in the product mix for rapid immunoassay COVID-19 products from higher-priced Sofia products sold in the professional market to lower-priced QuickVue products sold in the retail, pharmacy, and employer testing markets.

Revenue from COVID-19 products rose to $511.8 million from $405.3 million in the fourth quarter of 2020, with Douglas Bryant, President and CEO of Quidel, saying demand for COVID-19 testing remains elevated.

The company launched the Savanna MDx instrumented system in select markets during the quarter. Commenting on the system, Bryant said it is a "key near-term opportunity" for the company.

"Based on customer reviews in Europe, we believe Savanna will be a major growth driver, both in the U.S. and globally, for years to come," he added.

Related Articles

Quidel Rallies On Earnings Beat Despite Sales Decline

Jose Cuervo's parent firm Becle expects to hike prices this year

GE warns of profit hit in first half from supply and labor issues